

ARC
31



STATE OF NEW HAMPSHIRE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF PUBLIC HEALTH SERVICES

Lori A. Weaver
Interim Commissioner

Patricia M. Tilley
Director

29 HAZEN DRIVE, CONCORD, NH 03301
603-271-4501 1-800-852-3345 Ext. 4501
Fax: 603-271-4827 TDD Access: 1-800-735-2964 www.dhhs.nh.gov

January 9, 2023

The Honorable Ken Weyler, Chairman
Fiscal Committee of the General Court and

His Excellency, Governor Christopher T. Sununu
and the Honorable Council
State House
Concord, New Hampshire 03301

REQUESTED ACTION

Pursuant to RSA 14:30-a, VI, authorize the Department of Health and Human Services, Division of Public Health Services to accept and expend funds from the Centers for Disease Control and Prevention to fund New Hampshire's Epidemiology and Lab Capacity Program in the amount of \$2,251,560 effective upon approval by the Fiscal Committee and Governor and Executive Council through June 30, 2023, and further authorize these funds to be allocated as follows. 100% Federal Funds.

05-095-090-903010-XXXX0000 HEALTH AND SOCIAL SERVICES, DEPT OF HEALTH AND HUMAN SERVICES, HHS: PUBLIC HEALTH DIV, BUREAU OF LABORATORY SERVICES, EPI & LAB CAPACITY BP4-ARPA

Class-Account	Description	SFY 23 Current Adjusted Authorized	Requested Action	SFY 23 Revised Adjusted Authorized
Revenue				
000-406929-16	Federal Funds	\$ -	\$ 2,251,560	\$ 2,251,560
	Total Revenue:	\$ -	\$ 2,251,560	\$ 2,251,560

Class-Account	Description	SFY 23 Current Adjusted Authorized	Requested Action	SFY 23 Revised Adjusted Authorized
Expense				
020-500200	Current Expenses	\$ -	\$ 13,304	\$ 13,304
024-500225	Maint. Other than Build-Grn	\$ -	\$ 30,000	\$ 30,000
030-500301	Equipment New Replacement	\$ -	\$ 1,102,470	\$ 1,102,470
037-500173	Technology-Hardware	\$ -	\$ 15,491	\$ 15,491
038-500175	Technology-Software	\$ -	\$ 29,975	\$ 29,975
041-500801	Audit Fund Set Aside	\$ -	\$ 2,251	\$ 2,251
042-500620	Additional Fringe Benefits	\$ -	\$ 12,984	\$ 12,984
059-500117	Temp Full Time	\$ -	\$ 146,873	\$ 146,873
060-500601	Benefits	\$ -	\$ 76,400	\$ 76,400
070-500704	In-State Travel Reimbursement	\$ -	\$ 6,276	\$ 6,276
080-500714	Out of State Travel Reimb	\$ -	\$ 31,401	\$ 31,401
102-500731	Contracts for Program Services	\$ -	\$ 492,100	\$ 492,100
548-500396	Reagents	\$ -	\$ 292,035	\$ 292,035
	Total Expense:	\$ -	\$ 2,251,560	\$ 2,251,560

EXPLANATION

This request is being made to accept grant funds available from the Centers for Disease Control and Prevention (CDC) to support New Hampshire's Epidemiology and Lab Capacity Program.

The New Hampshire Epidemiology and Lab Capacity Program has been awarded ARPA funding to support the Advanced Molecular Detection (AMD) activities, including detection and surveillance of infectious diseases through Whole Genome Sequencing (WGS). The use of WGS allows for the improved detection and identification of pathogens as well as linking cases to determine outbreaks. This methodology is being expanded to include Tuberculosis, bacterial pathogens and viruses. The reagents and laboratory consumable supplies necessary for sequencing these pathogens can be very costly.

These funds will also be used to support the New Hampshire Public Health Lab's (NH PHL) partnership with the National Laboratory Response Network (LRN), which develops, maintains and strengthens an integrated domestic and international network of state laboratories to respond quickly to biological and chemical threats and other high-priority public health emergencies through training, rapid testing, timely notification, and secure messaging of laboratory results. These funds will maintain the NH PHL's ability to respond to public health events and emergencies, increase testing capabilities, increase security for the select agent program, and provide outreach, training and courier services to our partners. With rapid response capabilities, the NH PHL is able to provide timely results, which delivers faster treatment options as necessary.

These funds will also be used to support the National Wastewater Surveillance System (NWSS) which funds the COVID-19 wastewater surveillance program within New Hampshire. This surveillance program consists of collecting wastewater samples from treatment plants across NH. These samples are then processed and quantitatively tested for COVID-19 viral load. This funding will support Whole Genome Sequencing (WGS) of positive samples for variant strain surveillance. The data generated from this surveillance will be populated in a

publicly facing online dashboard, which will allow the citizens of New Hampshire to visualize COVID-19 prevalence in participating municipalities.

Without this funding, New Hampshire would be unable to implement and maintain the WGS testing at the New Hampshire Public Health Lab for existing and emerging pathogens, which would result in poorer health outcomes and more un-identified disease outbreaks for the citizens and visitors of New Hampshire. In addition, the NH PHL would be unable to implement and maintain the NWSS project, and the citizens of New Hampshire would be unaware of circulating COVID-19 levels in their communities, which could result in more COVID-19 outbreaks and a greater burden on the healthcare system.

Funds are to be budgeted as follows:

- Class 020 The funds will be used to cover operational expenses for the laboratory including copy and office supplies, laboratory supplies for outbreaks and testing agents, labels, headsets, conference and workshop supplies.
- Class 024 The funds will be used to purchase repairs for the Powered Air Purifying Respirators (PAPRs) in the Biosafety Laboratory that are used for high risk samples.
- Class 030 The funds will be used to purchase the following equipment needed at the NH Public Health Laboratory: Two freezers to store reagents, two refrigerators to store reagents, two biosafety cabinets, micro centrifuges, equipment for virtual reality courses, battery packs, incubators, digital PCR instrumentation, a liquid handling system, and a vacuum filtration system.
- Class 037 The funds will be used to purchase the following technological equipment for the program: laptop, monitor and docking station, label printers, workstations and desks, meeting microphones and speakers, scanners and printers.
- Class 038 The funds will be used to purchase Balsamiq Software required to plan and design the work the Laboratory IT performs prior to development.
- Class 041 The funds will be used to pay for audit fund set aside per state requirement.
- Class 042 The funds will be used to pay for Additional Fringe Benefits at 8.84% of full-time salaries.
- Class 059 The funds will be used to support existing full-time temporary positions, #8T3093 (Program Specialist IV), #8T3098 (Program Specialist III, Waterborne Disease Epidemiologist), #9T2885 (Microbiologist II).
- Class 060 The funds will be used to pay for benefits on the above positions.
- Class 070 The funds will be used for in state travel to conduct field work, investigations, presentations at conferences and meetings, and conduct trainings.
- Class 080 The funds will be used for out of state travel to the Council for States and Territorial Epidemiologists Conference and the Public Health Wastewater Disease Surveillance Summit.
- Class 102 The funds will be used to contract with vendors to provide services for the NH Public Health Laboratory. The Contractors include those for contracted services, data analysis, data analysis training and support, software and reporting, courier services, and annual maintenance and development for ESSENCE (Electronic Surveillance System for the Early Notification of Community-based Epidemics).
- Class 548 The funds will be used to purchase reagents needed for the NH Public Health Laboratory, including WGS reagent cartridges, WGS library preparation kits, WGS indexing kit samples, PCR supplies for COVID-19 testing, RNA extraction supplies for testing, Bruker MALDI-TOF supplies, Kingfisher supplies and pipets.

In response to the anticipated two-part question, "Can these funds be used to offset General Funds?" and "What is the compelling reason for not offsetting General Funds?" the Division offers the following information: The funds are provided for a specified purpose by the Centers for Disease Control as defined in the Notice of Grant Award and cannot be used to offset general funds.


The Honorable Ken Weyler, Chairman
His Excellency, Governor Christopher T. Sununu
Page 4 of 4

Area served: Statewide.

Source of funds: 100% Federal funds from the Centers for Disease Control and Prevention, Epidemiology and Lab Capacity Program.

If Federal Funds become no longer available, additional General Funds will not be requested to support the program.

Respectfully submitted,

 For:

Lori A. Weaver
Interim Commissioner



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award#: 5 NU50CK000522-04-00

FAIN#: NU50CK000522

Federal Award Date: 07/12/2022

Recipient Information

1. Recipient Name
 Health and Human Services, New Hampshire Dept of
 129 Pleasant St
 Concord, NH 03301-3852
 [NO DATA]

2. Congressional District of Recipient
 02

3. Payment System Identifier (ID)
 1026000618B3

4. Employer Identification Number (EIN)
 026000618

5. Data Universal Numbering System (DUNS)
 011040545

6. Recipient's Unique Entity Identifier (UEI)
 LA2HR1U97VC6

7. Project Director or Principal Investigator
 Mrs. Chiahui Chawla
 Chief, Bureau of Public Health Statistics and
 Informatics
 Chiahui.S.Chawla@dhhs.nh.gov

8. Authorized Official
 Ms. Richelle Swanson
 AO / Financial Administrator
 Richelle.Swanson@dhhs.nh.gov
 603-271-4613

Federal Agency Information
CDC Office of Financial Resources

9. Awarding Agency Contact Information
 Ms. Joelle Cadet
 Grants Management Specialist
 qrx2@cdc.gov
 (404) 498-4349

10. Program Official Contact Information
 Mr. Fred Maxineau
 PHA
 hyx2@cdc.gov
 404.639.0869

Federal Award Information

11. Award Number
 5 NU50CK000522-04-00

12. Unique Federal Award Identification Number (FAIN)
 NU50CK000522

13. Statutory Authority
 301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title
 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

15. Assistance Listing Number
 93.323

16. Assistance Listing Program Title
 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type
 Non-Competing Continuation

18. Is the Award R&D?
 No

Summary Federal Award Financial Information

19. Budget Period Start Date	08/01/2022	- End Date	07/31/2023
20. Total Amount of Federal Funds Obligated by this Action	\$4,535,431.00		
20a. Direct Cost Amount	\$3,882,341.00		
20b. Indirect Cost Amount	\$653,090.00		
21. Authorized Carryover	\$0.00		
22. Offset	\$0.00		
23. Total Amount of Federal Funds Obligated this budget period	\$0.00		
24. Total Approved Cost Sharing or Matching, where applicable	\$0.00		
25. Total Federal and Non-Federal Approved this Budget Period	\$4,535,431.00		
26. Period of Performance Start Date	08/01/2019	- End Date	07/31/2024
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance	\$213,088,639.00		

28. Authorized Treatment of Program Income
 ADDITIONAL COSTS

29. Grants Management Officer - Signature
 Ms. Freda Johnson
 Grants Management Officer

30. Remarks

See Remarks (continuation)



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 5 NU50CK000522-04-00
 FAIN# NU50CK000522
 Federal Award Date: 07/12/2022

Recipient Information	
Recipient Name Health and Human Services, New Hampshire Dept of 129 Pleasant St Concord, NH 03301-3852 [NO DATA]	
Congressional District of Recipient 02	
Payment Account Number and Type 1026000618B3	
Employer Identification Number (EIN) Data 026000618	
Universal Numbering System (DUNS) 011040545	
Recipient's Unique Entity Identifier (UEI) LA2HRIU97VC6	
31. Assistance Type Cooperative Agreement	
32. Type of Award Other	

33. Approved Budget (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$968,987.00
b. Fringe Benefits	\$626,233.00
c. Total Personnel Costs	\$1,595,220.00
d. Equipment	\$1,107,730.00
e. Supplies	\$440,110.00
f. Travel	\$128,110.00
g. Construction	\$0.00
h. Other	\$154,911.00
i. Contractual	\$456,260.00
j. TOTAL DIRECT COSTS	\$3,882,341.00
k. INDIRECT COSTS	\$653,090.00
l. TOTAL APPROVED BUDGET	\$4,535,431.00
m. Federal Share	\$4,535,431.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
0-9390EPX	19NU50CK000522CV	CK	41.51	93.323	\$0.00	75-2022-0943
1-9390EWQ	19NU50CK000522C3	CK	41.51	93.323	\$0.00	75-2024-0943
0-93907F	19NU50CK000522C4	CK	41.51	93.323	\$0.00	75-X-0140
1-9390GCP	19NU50CK000522AMDC4	CK	41.51	93.323	\$0.00	75-X-0943
1-9390GCQ	19NU50CK000522THC4	CK	41.51	93.323	\$0.00	75-X-0943
1-9390GFO	19NU50CK000522PHLC4	CK	41.51	93.323	\$0.00	75-X-0943
1-9390GF6	19NU50CK000522PHL2C6	CK	41.51	93.323	\$0.00	75-X-0140
1-9390GKT	19NU50CK000522EEXC5	CK	41.51	93.323	\$0.00	75-2122-0140
1-9390GY2	19NU50CK000522SCHLC6	CK	41.51	93.323	\$0.00	75-X-0140
1-9390H08	19NU50CK000522AMD2C6	CK	41.51	93.323	\$0.00	75-X-0943
2-9211175	19NU50CK000522	CK	41.51	93.323	\$57,000.00	75-22-0949
2-9211457	19NU50CK000522	CK	41.51	93.323	\$206,845.00	75-22-0949
2-939014P	19NU50CK000522	CK	41.51	93.323	\$18,683.00	75-22-0949
2-939017Y	19NU50CK000522	CK	41.51	93.323	\$168,343.00	75-X-0943
2-93904SH	19NU50CK000522	CK	41.51	93.323	\$193,310.00	75-22-0959
2-93905VH	19NU50CK000522	CK	41.51	93.323	\$77,398.00	75-22-0949
2-93906EZ	19NU50CK000522	CK	41.51	93.323	\$25,491.00	75-22-0947
2-93907PM	19NU50CK000522	CK	41.51	93.323	\$1,000.00	75-X-0951
2-93908MV	19NU50CK000522	CK	41.51	93.323	\$436,817.00	75-22-0949
2-9390ASV	19NU50CK000522	CK	41.51	93.323	\$172,425.00	75-22-0951
2-9390ETG	19NU50CK000522MISCCO	CK	41.51	93.323	\$87,837.00	75-2022-0943
2-9390G29	19NU50CK000522	CK	41.51	93.323	\$19,262.00	75-22-0951
2-9390J85	19NU50CK000522	CK	41.51	93.323	\$229,778.00	75-X-0949
2-9390JAE	19NU50CK000522LRNC6	CK	41.51	93.323	\$929,856.00	75-X-0140
2-9390JAX	19NU50CK000522SNETC6	CK	41.51	93.323	\$87,243.00	75-X-0140
2-9390JEN	19NU50CK000522NWSSC6	CK	41.51	93.323	\$1,340,758.00	75-X-0140
2-9390JGE	19NU50CK000522	CK	41.51	93.323	\$54,170.00	75-X-0951
2-9390JLQ	19NU50CK000522	CK	41.51	93.323	\$21,372.00	75-X-0951
2-939ZLBF	19NU50CK000522	CK	41.51	93.323	\$6,942.00	75-22-0951
2-939ZRVU	19NU50CK000522	CK	41.51	93.323	\$25,253.00	75-22-0951



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU50CK000522-04-00
FAIN# NU50CK000522
Federal Award Date: 07/12/2022

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
2-939ZSER	19NU50CK000522	CK	41.51	93.323	\$3,599.00	75-22-0949
2-939ZSKU	19NU50CK000522	CK	41.51	93.323	\$58,832.00	75-22-0949
12-939ZVJC	19NU50CK000522	CK	41.51	93.323	\$313,217.00	75-22-0949



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU50CK000522-04-00

FAIN# NU50CK000522

Federal Award Date: 07/12/2022

Remarks (Continuation).

YR04 Initial Continuation funding.

- Access to the General Terms and Conditions: Recipients must also adhere to the General Terms and Conditions for Non-Research awards. The General Terms and Conditions may be accessed by clicking on the hyperlink embedded within the attached Terms and Conditions

- Due to technical issues beyond our control within GrantSolutions, OGS is unable to expand previous document numbers into BP4 under this award action. Once the issue has been resolved, a subsequent award action to extend the document numbers will be issued.



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU50CK000522-04-00

FAIN# NU50CK000522

Federal Award Date: 07/12/2022

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Health and Human Services, New Hampshire Dept of

5 NU50CK000522-04-00

1. Terms and Conditions YR4 Non Competing Continuation

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, titled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)*, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of \$4,535,431 is approved for the Year 04 budget period, which is August 1, 2022 through July 31, 2023. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

Funding Component	Location in Budget	Common Account Number (CAN)	Document Suffix	Amount
Core funding	A1 - W budget tabs	Multiple	N/A	\$2,089,737
Laboratory Response Network (LRN)	A2 budget tab	939-OJAE	-LRNC6	\$929,856
National Wastewater Surveillance System (NWSS)	F1 & F2 budget tabs	939-OJEN	-NWSSC6	\$1,340,758
MIS-C	O Budget tab	939-OETG	-MISCC0	\$ 87,837
SET-NET	W budget tab	939-OJAX	-SNETC6	\$ 87,243

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in

consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

- National coordination of activities where appropriate.
- Targeted Electronic Data Exchange (EDX) technical assistance to public health departments and public health labs.

Administrative Requirement: The recipient must respond to the budget mark-up comments in accordance with the recommendations provided in GrantSolutions as a Grant Note within 60 days of issuance of the Notice of Award. If the date falls on a weekend or holiday, the submission will be due the following business day.

To be considered an official response, recipients must:

1. Use the Excel file labeled '[Recipient]-BP4-Budget-Master-MarkedUp-FINAL' as this is the ELC budget workbook. This budget workbook is provided in Grant Notes at time the revised NOA is issued.
2. Go to the 'CDC Program Notes Report' tab in the budget workbook.
3. For each line item that has been flagged, provide the requested information in the

Recipient Response section.

4. Once completed, generate a PDF of the 'CDC Program Notes Report' and submit in GrantSolutions via Grant Note.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs: Indirect costs are approved based on the recipient's approved Cost Allocation Plan dated September 30, 2021.

REPORTING REQUIREMENTS

Financial Reporting Requirement:

COVID-19:

- Monthly fiscal reports, beginning 30 days after NOAs are issued. Reporting is due on the 5th of the next month, or next business day if the 5th falls on a weekend or federal holiday. For example, August financial reporting is due September 5 and should cover August 1 - 31 spending. Reporting must include both expenditures and unliquidated obligations (ULOs). Reporting is required until all funds are fully expended. Reporting is done in REDCap with a final PDF generated and submitted in GrantSolutions via Grant Note.

CORE:

- Quarterly reporting is due on the 5th of the next month, or next business day if the 5th falls on a weekend or federal holiday. For example, the Quarter 1 (i.e., August through October) reporting is due November 5 and should cover the August 1 - October 31 spending. Reporting must include both expenditures and unliquidated obligations (ULOs). Reporting is required for all 4 quarters.

Additional Reporting Requirements:

- Quarterly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans
- Quarterly Performance measure data
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):

Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Joëlle Cadet, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Email: grx2@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 2 of the Notice of Award must be known in order to draw down funds.

CDG Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.